Literature DB >> 22966128

Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with Staphylococcus aureus bacteremia.

Warren E Rose1, Jens C Eickhoff, Sanjay K Shukla, Madhulatha Pantrangi, Suzan Rooijakkers, Sara E Cosgrove, Victor Nizet, George Sakoulas.   

Abstract

BACKGROUND: Staphylococcus aureus bacteremia (SaB) carries considerable morbidity and mortality. We examined the predictive value of serum concentrations of interleukin (IL)-10, proinflammatory cytokines, and terminal complement on patient survival and SaB duration.
METHODS: Clinical information on consecutive patients with SaB at a tertiary medical center were collected prospectively. Patient serum samples obtained at the day of clinical presentation were assayed for tumor necrosis factor-α, IL-1β, IL-10, and complement membrane attack complex C5b-9 concentrations using enzyme-linked immunoassay. Logistic regression identified predictors of mortality and duration of bacteremia.
RESULTS: In 59 patients with SaB, 14% died and 17% had prolonged bacteremia (>4 days). Elevated IL-10 serum concentrations (>7.8 pg/mL) identified all 8 patients who died, whereas there were no deaths in patients with normal IL-10 (P = .016). The lack of an IL-1β response (≤0.45 pg/mL) defined all patients with SaB >4 days. In multivariate analysis, patient age (odds ratio [OR], 1.16; P = .022), duration of bacteremia (OR, 1.16; P = .031), and serum IL-10 (OR, 1.05; P = .014) were identified as independent predictors of patient mortality.
CONCLUSIONS: SaB mortality was confined strictly to patients with elevated IL-10 concentrations. We recommend that future clinical trials of SaB stratify patients according to IL-10 and IL-1β serum concentrations in order to better evaluate the impact of therapeutic interventions on patient outcome.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22966128      PMCID: PMC6281403          DOI: 10.1093/infdis/jis552

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  14 in total

1.  Protective role of complement C5a in an experimental model of Staphylococcus aureus bacteremia.

Authors:  Maren von Köckritz-Blickwede; Stephanie Konrad; Simon Foster; J Engelbert Gessner; Eva Medina
Journal:  J Innate Immun       Date:  2009-10-10       Impact factor: 7.349

2.  Toll-like receptor 2 ligands on the staphylococcal cell wall downregulate superantigen-induced T cell activation and prevent toxic shock syndrome.

Authors:  Thu A Chau; Michelle L McCully; William Brintnell; Gary An; Katherine J Kasper; Enrique D Vinés; Paul Kubes; S M Mansour Haeryfar; John K McCormick; Ewa Cairns; David E Heinrichs; Joaquín Madrenas
Journal:  Nat Med       Date:  2009-06       Impact factor: 53.440

3.  Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations.

Authors:  Natasha E Holmes; John D Turnidge; Wendy J Munckhof; James O Robinson; Tony M Korman; Matthew V N O'Sullivan; Tara L Anderson; Sally A Roberts; Wei Gao; Keryn J Christiansen; Geoffrey W Coombs; Paul D R Johnson; Benjamin P Howden
Journal:  J Infect Dis       Date:  2011-08-01       Impact factor: 5.226

4.  Anti-inflammatory cytokine profile and mortality in febrile patients.

Authors:  J T van Dissel; P van Langevelde; R G Westendorp; K Kwappenberg; M Frölich
Journal:  Lancet       Date:  1998-03-28       Impact factor: 79.321

5.  Complement depletion during haemofiltration with polyacrilonitrile membranes.

Authors:  Y Gasche; M Pascual; P M Suter; H Favre; J C Chevrolet; J A Schifferli
Journal:  Nephrol Dial Transplant       Date:  1996-01       Impact factor: 5.992

6.  Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Alex Soriano; Francesc Marco; José A Martínez; Elena Pisos; Manel Almela; Veselka P Dimova; Dolores Alamo; Mar Ortega; Josefina Lopez; Josep Mensa
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

7.  Role of peptidoglycan from Staphylococcus aureus in leukopenia, thrombocytopenia, and complement activation associated with bacteremia.

Authors:  J S Spika; P K Peterson; B J Wilkinson; D E Hammerschmidt; H A Verbrugh; J Verhoef; P G Quie
Journal:  J Infect Dis       Date:  1982-08       Impact factor: 5.226

8.  Impaired lung defenses against Staphylococcus aureus in mice with hereditary deficiency of the fifth component of complement.

Authors:  M C Cerquetti; D O Sordelli; R A Ortegon; J A Bellanti
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

9.  Based Upon Repeat Pattern (BURP): an algorithm to characterize the long-term evolution of Staphylococcus aureus populations based on spa polymorphisms.

Authors:  Alexander Mellmann; Thomas Weniger; Christoph Berssenbrügge; Jörg Rothgänger; Michael Sammeth; Jens Stoye; Dag Harmsen
Journal:  BMC Microbiol       Date:  2007-10-29       Impact factor: 3.605

10.  Staphylococcal complement evasion by various convertase-blocking molecules.

Authors:  Ilse Jongerius; Jörg Köhl; Manoj K Pandey; Maartje Ruyken; Kok P M van Kessel; Jos A G van Strijp; Suzan H M Rooijakkers
Journal:  J Exp Med       Date:  2007-09-24       Impact factor: 14.307

View more
  58 in total

1.  Interleukin (IL)-1β and IL-10 Host Responses in Patients With Staphylococcus aureus Bacteremia Determined by Antimicrobial Therapy.

Authors:  Cecilia F Volk; Sarah Burgdorf; Graham Edwardson; Victor Nizet; George Sakoulas; Warren E Rose
Journal:  Clin Infect Dis       Date:  2020-06-10       Impact factor: 9.079

2.  Evidence To Support Continuation of Statin Therapy in Patients with Staphylococcus aureus Bacteremia.

Authors:  Aisling R Caffrey; Tristan T Timbrook; Eunsun Noh; George Sakoulas; Steven M Opal; Victor Nizet; Kerry L LaPlante
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

Review 3.  Avoiding the perfect storm: the biologic and clinical case for reevaluating the 7-day expectation for methicillin-resistant Staphylococcus aureus bacteremia before switching therapy.

Authors:  Ravina Kullar; James A McKinnell; George Sakoulas
Journal:  Clin Infect Dis       Date:  2014-07-21       Impact factor: 9.079

4.  A new simplified predictive model for mortality in methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Sarah C J Jorgensen; Abdalhamid M Lagnf; Sahil Bhatia; Michael J Rybak
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-02-08       Impact factor: 3.267

5.  Interleukin-10 (IL-10) Produced by Mutant Toxic Shock Syndrome Toxin 1 Vaccine-Induced Memory T Cells Downregulates IL-17 Production and Abrogates the Protective Effect against Staphylococcus aureus Infection.

Authors:  Kouji Narita; Dong-Liang Hu; Krisana Asano; Akio Nakane
Journal:  Infect Immun       Date:  2019-09-19       Impact factor: 3.441

Review 6.  Is a Reported Penicillin Allergy Sufficient Grounds to Forgo the Multidimensional Antimicrobial Benefits of β-Lactam Antibiotics?

Authors:  George Sakoulas; Matthew Geriak; Victor Nizet
Journal:  Clin Infect Dis       Date:  2019-01-01       Impact factor: 9.079

7.  Uncoupling of pro- and anti-inflammatory properties of Staphylococcus aureus.

Authors:  Adam G Peres; Camille Stegen; Junbin Li; An Qi Xu; Benoit Levast; Michael G Surette; Benoit Cousineau; Martin Desrosiers; Joaquín Madrenas
Journal:  Infect Immun       Date:  2015-02-02       Impact factor: 3.441

8.  Staphylococcal Enterotoxin B-specific monoclonal antibody 20B1 successfully treats diverse Staphylococcus aureus infections.

Authors:  Avanish K Varshney; Xiaobo Wang; Matthew D Scharff; Jennifer MacIntyre; Richard S Zollner; Oleg V Kovalenko; Luis R Martinez; Fergus R Byrne; Bettina C Fries
Journal:  J Infect Dis       Date:  2013-08-06       Impact factor: 5.226

Review 9.  Where does a Staphylococcus aureus vaccine stand?

Authors:  V G Fowler; R A Proctor
Journal:  Clin Microbiol Infect       Date:  2014-05       Impact factor: 8.067

Review 10.  Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies.

Authors:  Fabienne Venet; Anne-Claire Lukaszewicz; Didier Payen; Richard Hotchkiss; Guillaume Monneret
Journal:  Curr Opin Immunol       Date:  2013-05-28       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.